Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 1530 | 351.725 |
09:36 ET | 100 | 351.495 |
09:43 ET | 100 | 352.77 |
09:45 ET | 200 | 354.162 |
09:48 ET | 100 | 353.385 |
09:50 ET | 106 | 353.015 |
09:56 ET | 512 | 351.72 |
09:57 ET | 100 | 351.715 |
10:01 ET | 815 | 351.93 |
10:10 ET | 100 | 353 |
10:15 ET | 403 | 352.99 |
10:17 ET | 1100 | 352.75 |
10:19 ET | 200 | 352.3801 |
10:21 ET | 100 | 353.22 |
10:24 ET | 992 | 352.256205 |
10:26 ET | 214 | 352.77 |
10:32 ET | 300 | 351.49 |
10:33 ET | 3632 | 351.325 |
10:37 ET | 300 | 352.285 |
10:44 ET | 400 | 351.44 |
10:48 ET | 100 | 351.615 |
10:53 ET | 100 | 351.965 |
11:00 ET | 300 | 352.17 |
11:04 ET | 200 | 351.985 |
11:06 ET | 200 | 352.125 |
11:15 ET | 300 | 352.2 |
11:20 ET | 900 | 351.77 |
11:24 ET | 229 | 351.585 |
11:33 ET | 400 | 351.795 |
11:36 ET | 100 | 352.07 |
11:40 ET | 200 | 352.325 |
11:42 ET | 400 | 351.85 |
11:54 ET | 224 | 352.45 |
12:00 ET | 100 | 352.45 |
12:02 ET | 100 | 352.46 |
12:03 ET | 509 | 352.335 |
12:09 ET | 200 | 353.14 |
12:16 ET | 100 | 352.92 |
12:20 ET | 100 | 353.065 |
12:21 ET | 637 | 353.1937 |
12:23 ET | 100 | 353.4 |
12:25 ET | 200 | 353.455 |
12:27 ET | 300 | 353.45 |
12:30 ET | 100 | 353.45 |
12:34 ET | 100 | 353.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.6B | 16.2x | +8.22% |
Biomarin Pharmaceutical Inc | 13.0B | 51.9x | --- |
Exact Sciences Corp | 12.3B | -70.1x | --- |
Neurocrine Biosciences Inc | 11.3B | 34.2x | +62.04% |
Medpace Holdings Inc | 10.5B | 32.1x | +35.10% |
Qiagen NV | 9.7B | 135.8x | +12.66% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.6B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.2x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | 13.8x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.